IND submission is a major milestone in the life of your drug. We can provide all supporting analytical data to help ensure a smooth application process.
We have the expertise, flexibility, and resources to provide a full range of pharmaceutical API custom development services at every stage of the lifecycle.
We can provide lab-, kilo- and pilot-scale manufacturing for preclinical studies and all phases of clinical trials, supplying milligram to kilogram quantities.
Cambrex brings more than 40 years of generic API manufacturing experience to its pharmaceutical partners. From our sites in Italy, Sweden, and the USA, we are a leading global supplier of generic APIs.
Drug substance tech transfer sounds so simple on the surface, but it’s a complex activity carrying a number of technical, regulatory, and quality risks.
At Snapdragon Chemistry, now part of Cambrex, our chemists specialize in creating custom solutions and technologies to take on your toughest process development and production challenges. This includes expertise in designing and building reactors that enable seamless technology transfer as a process scales up for commercial manufacturing.
At Cambrex, we provide a range of technologies equipped to solve your API manufacturing challenges, and we are flexible enough to handle the most complex molecules.
You can rely on our extensive portfolio of analytical development solutions and testing services to rapidly advance your molecule for the greatest chance of success.
Cambrex offers a comprehensive suite of testing services for complex biopharmaceuticals including standalone analytical R&D, method validation, release testing, ICH stability, and routine QC testing.
We’re solid state chemistry experts who can deliver timely, phase-appropriate solutions to optimize the physical stability of your API, develop a more bioavailable formulation or overcome other challenges.
Cambrex’s experienced analysts are well-equipped to ensure microbial testing is of the highest quality for our customers and delivered with a quick and reliable turnaround.
Cambrex and Q1 Scientific’s stability storage and sample management capabilities provide a variety of pharmaceutical storage conditions, with walk-in and reach-in chambers that meet all ICH Q1A requirements.
Cambrex offers extensive development services tailored to meet your drug product needs in early development. From pre-formulation to Phase II, we ensure your products are developed with speed, flexibility, and quality in mind.
Whether you need rapid development, flexible manufacturing solutions, or high-quality production, Cambrex is your trusted partner for advancing your drug product from concept to the clinic.
Cambrex is here to support you in early-phase development. Our development experts apply their ingenuity and skill to address your unique challenges.
Our teams of creative problem-solvers work closely with you to accelerate drug development timelines, optimize processes, and meet regulatory requirements.
We understand that the commercial phase of drug development can be challenging, especially when it comes to manufacturing at scale and meeting changing market demands.
Cambrex is a leading global supplier of more than 70 generic APIs, as well as intermediates and derivatives.
09.27.2011
East Rutherford, NJ – Cambrex Corporation (NYSE: CBM, “Cambrex”) will be exhibiting at the 2011 American Association of Pharmaceutical Sciences (AAPS) Meeting and Exposition, October 24-27 in Washington, DC. Attendees are invited to visit Cambrex’s booth to learn about the Company’s wide range of custom development and manufacturing services as well as several innovative technologies for the pharmaceutical industry.
Cambrex offers small molecule Active Pharmaceutical Ingredients (APIs) and process development services for proprietary APIs as well as technologies, including Camouflage® taste-masking technology, that enhances the efficacy of finished drug products. Camouflage® drug delivery technology will be the focus of AAPS. Camouflage® is a polymer resin-based drug delivery platform that provides improved drug stability, the ability to control drug release and taste-masking as its major benefits and is a novel approach to dealing with many critical aspects of drug delivery. Cambrex has assisted innovator and generic drug companies in the commercialization of a number of important orally-dosed drug products based on this technology and Camouflage® has been deployed in a variety of dosage forms.
Cambrex specializes in finished dosage form development to assist with the commercialization of products through its Cambrex Zenara facility located in Hyderabad, India. Cambrex Zenara provides high quality and competitively priced pharmaceutical drug product, formulation, development and manufacturing capabilities designed to accelerate commercialization of finished drug products for the pharmaceutical industry with specific expertise in Nicotine Replacement Therapy (NRT). In December 2010, Cambrex Zenara began supplying an NRT product to support a commercial launch in the Indian market.
Cambrex will also be showcasing its global development and manufacturing capabilities including specialized offerings related to DEA controlled substances, high potency APIs and high energy chemistries. Cambrex manufactures over 120 generic and branded APIs and advanced intermediate products for the pharmaceutical and biopharma industry.
Cambrex will be exhibiting at Booth 1146 at the Walter E. Washington Convention Center, Washington, DC.